Մալթա - անգլերեն - Medicines Authority

accord healthcare limited - cinacalcet hydrochloride - film-coated tablet - cinacalcet hydrochloride 60 mg - calcium homeostasis

Մալթա - անգլերեն - Medicines Authority

accord healthcare limited - cinacalcet hydrochloride - film-coated tablet - cinacalcet hydrochloride 90 mg - calcium homeostasis

Մալթա - անգլերեն - Medicines Authority

accord healthcare limited - atosiban acetate - concentrate for solution for infusion - atosiban acetate 37.5 mg - other gynecologicals

Եվրոպական Միություն - անգլերեն - EMA (European Medicines Agency)

accord healthcare s.l.u. - docetaxel - head and neck neoplasms, carcinoma, non-small-cell lung, adenocarcinoma, prostatic neoplasms, breast neoplasms - antineoplastic agents, - breast cancerdocetaxel accord in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.for patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.docetaxel accord in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.docetaxel accord monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent.docetaxel accord in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer w

Եվրոպական Միություն - անգլերեն - EMA (European Medicines Agency)

accord healthcare s.l.u. - docetaxel - head and neck neoplasms, carcinoma, non-small-cell lung, adenocarcinoma, prostatic neoplasms, breast neoplasms - antineoplastic agents, - breast cancerdocetaxel accord in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.for patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.docetaxel accord in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.docetaxel accord monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent.docetaxel accord in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer w

Միացյալ Թագավորություն - անգլերեն - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - paracetamol - effervescent tablet - 500mg

Իռլանդիա - անգլերեն - HPRA (Health Products Regulatory Authority)

accord healthcare limited - atosiban - solution for injection in pre-filled syringe - 6.75 milligram - atosiban

Հայաստան - անգլերեն - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

accord healthcare limited - naproxen - tablets - 500mg

Իռլանդիա - անգլերեն - HPRA (Health Products Regulatory Authority)

accord healthcare limited - alendronic acid - tablets - 70 milligram - alendronic acid

Իռլանդիա - անգլերեն - HPRA (Health Products Regulatory Authority)

accord healthcare limited - anastrozole - film coated tablet - 1 milligram - anastrozole